Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported And Analysts Have Been Lifting Their Price Targets [Yahoo! Finance]
Fate Therapeutics, Inc. (FATE)
Last fate therapeutics, inc. earnings: 3/2 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.fatetherapeutics.com/investor-relations
Company Research
Source: Yahoo! Finance
The results look positive overall; while revenues of US$64m were in line with analyst predictions, statutory losses were 4.3% smaller than expected, with Fate Therapeutics losing US$1.64 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year. See our latest analysis for Fate Therapeutics After the latest results, the consensus from Fate Therapeutics' 16 analysts is for revenues of US$4.81m in 2024, which would reflect a painful 92% decline in revenue compared to the last year of performance. Per-share losses are supposed to see a sharp uptick, reaching US$1.90. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$5.97m and losses of US$2.04 per share in 2024. So there's be
Show less
Read more
Impact Snapshot
Event Time:
FATE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FATE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FATE alerts
High impacting Fate Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FATE
News
- Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $7.00 price target on the stock.MarketBeat
- Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates [Yahoo! Finance]Yahoo! Finance
- Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational UpdatesGlobeNewswire
- Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual MeetingGlobeNewswire
- Fate Therapeutics: Looking For A Potential Turnaround In 2024 [Seeking Alpha]Seeking Alpha
FATE
Earnings
- 2/26/24 - Beat
FATE
Sec Filings
- 5/2/24 - Form 424B3
- 4/30/24 - Form EFFECT
- 4/26/24 - Form ARS
- FATE's page on the SEC website